Cartesian Therapeutics (RNAC) Invested Capital (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Invested Capital for 11 consecutive years, with -$126.2 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital fell 1755.92% to -$126.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$126.2 million, a 1755.92% decrease, with the full-year FY2025 number at -$126.2 million, down 1755.92% from a year prior.
- Invested Capital was -$126.2 million for Q4 2025 at Cartesian Therapeutics, down from -$35.8 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $102.3 million in Q4 2022 to a low of -$411.9 million in Q4 2023.
- A 5-year average of -$13.3 million and a median of -$2.2 million in 2021 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: surged 4910.51% in 2022, then tumbled 4866.49% in 2025.
- Cartesian Therapeutics' Invested Capital stood at $28.5 million in 2021, then surged by 259.19% to $102.3 million in 2022, then plummeted by 502.6% to -$411.9 million in 2023, then skyrocketed by 98.35% to -$6.8 million in 2024, then crashed by 1755.92% to -$126.2 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Invested Capital are -$126.2 million (Q4 2025), -$35.8 million (Q3 2025), and -$2.5 million (Q2 2025).